Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 14, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 14, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14 | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 335,498 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: Includes 517 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021. F3: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy the Michael D.Clayman 2006 Revocable Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 373,769 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy the Michael D. Clayman Irrevocable Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 24,600 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Development Fund III, LLC | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 388,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F4: Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2023-07-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 136,530 · Balance 0 F5: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2024-03-02 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.91 · Expires 2025-01-20 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 110,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2026-01-03 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 155,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2026-12-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 175,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.31 · Expires 2028-01-31 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-11-19 · Disposition to issuer · Disposed 116,667 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-11-19 · Disposition to issuer · Disposed 290,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2030-03-01 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-11-19 · Disposition to issuer · Disposed 185,000 · Balance 0 F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Performance Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-19 · Disposition to issuer · Disposed 106,100 · Balance 0 F7: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: Includes 517 shares of Issuer common stock acquired under the Issuer's 2013 Employee Stock Purchase Plan on November 17, 2021.
F3: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F4: Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
F5: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) any potential CVR Payments, net of any withholding taxes required to be deducted and withheld by applicable legal requirements.
F6: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
F7: At the effective time of the Merger, each outstanding restricted stock unit award conditioned on performance metrics ("PSU") was accelerated (assuming achievement at 100% of the applicable target levels) and became fully vested and cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such PSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2018 Filed Oct 9, 2018 16:31 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 6,233 | $18.60 | $115,933.80 |
DisclosureSEC source: 0001209191-18-054525 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,849 Read SEC document |
| October 08, 2018 Filed Oct 9, 2018 16:31 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 14,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-054525 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 09:13 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 10,000 | $22.33 | $223,300.00 |
DisclosureSEC source: 0001209191-18-046129 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,282 Read SEC document |
| June 27, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 5 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 294,937 Read SEC document |
| June 27, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,295 Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 16:33 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 554 | $21.22 | $11,755.88 |
DisclosureSEC source: 0001209191-18-039220 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,282 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 554 shares by the Reporting Person on June 20, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 12:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001562180-18-003015 · primarydocument.xml · derivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-14 F1 · shares: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. Read SEC document |
| February 27, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 10,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 6 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 305,499 Read SEC document |
| February 27, 2018 Filed Nov 13, 2018 09:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 10,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058086 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,733 Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 16:41 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 116,667 | $0.00 Strike: $22.31 | $0.00 |
DisclosureSEC source: 0001209191-18-006915 · doc4.xml · derivative · entry 5 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,667 Underlying: Common Stock · 116,667 shares Expires 2028-01-31 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of January 1, 2018, so that all of the shares subject to the option shall be vested four (4) years after January 1, 2018. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 16:41 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 29,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-006915 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,728 Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 17:05 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 166 | $16.59 | $2,753.94 |
DisclosureSEC source: 0001209191-17-067095 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,561 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 166 shares by the Reporting Person on December 20, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 08, 2017 Filed Nov 9, 2017 09:13 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 5,000 | $23.60 | $118,000.00 |
DisclosureSEC source: 0001209191-17-059880 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,395 Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 16:39 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionRestricted Stock Unit Award · Derivative | 14,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056478 · doc4.xml · derivative · entry 6 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 14,800 shares Expires 2019-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015. On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows: 14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 16:39 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Tax withholdingCommon Stock | 5,794 | $29.93 | $173,442.81 |
DisclosureSEC source: 0001209191-17-056478 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,395 Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 16:39 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 14,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-056478 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 20, 2017 Filed Jun 23, 2017 18:36 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 1,243 | $15.37 | $19,104.91 |
DisclosureSEC source: 0001209191-17-041751 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,389 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,243 shares by the Reporting Person on June 20, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001562180-17-002293 · primarydocument.xml · derivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the option shares vest on the first anniversary of the date of grant (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:47 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 5,000 | $17.23 | $86,151.50 |
DisclosureSEC source: 0001209191-17-038221 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,146 F1 · price: The weighted average purchase price for the transaction reported was $17.23030, and the range of prices were between $17.22580 and $17.23980. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 16:34 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001209191-16-156527 · doc4.xml · derivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2026-12-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after December 20, 2016; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of December 20, 2016, so that all of the shares subject to the option shall be vested four (4) years after December 20, 2016. Read SEC document |
| December 20, 2016 Filed Dec 27, 2016 16:58 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 147 | $9.01 | $1,324.47 |
DisclosureSEC source: 0001209191-16-156827 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,868 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 147 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan. F1 · shares: This Form 4 is being filed voluntarily to report the acquisition of 147 shares by the Reporting Person on December 20, 2016 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 20:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 1,667 | $18.41 | $30,688.30 |
DisclosureSEC source: 0001209191-16-152006 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,721 F1 · price: The weighted average purchase price for the transaction reported was $18.4093, and the range of prices were between $18.13 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 08:35 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 1,666 | $17.95 | $29,900.20 |
DisclosureSEC source: 0001209191-16-151827 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,054 F1 · price: The weighted average purchase price for the transaction reported was $17.94730, and the range of prices were between $17.76 and $18.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 14:28 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 1,666 | $17.90 | $29,827.40 |
DisclosureSEC source: 0001209191-16-151664 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,388 F1 · price: The weighted average purchase price for the transaction reported was $17.90360, and the range of prices were between $17.70 and $18.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 21, 2016 Filed Mar 10, 2017 17:03 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 15,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019900 · doc4.xml · nonDerivative · entry 2 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael D.Clayman 2006 Revocable Trust Disclosed balance after: 294,383 Read SEC document |
| June 21, 2016 Filed Mar 10, 2017 17:03 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GiftCommon Stock | 15,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019900 · doc4.xml · nonDerivative · entry 1 Clayman Michael D. · CIK 0001597407 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,146 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.